DEFERIPRONE ( DrugBank: Deferiprone )


6 diseases
告示番号疾患名(ページ内リンク)臨床試験数
2筋萎縮性側索硬化症4
6パーキンソン病15
18脊髄小脳変性症(多系統萎縮症を除く。)2
120遺伝性ジストニア10
122脳表ヘモジデリン沈着症2
233ウォルフラム症候群1

2. 筋萎縮性側索硬化症


臨床試験数 : 624 薬物数 : 623 - (DrugBank : 160) / 標的遺伝子数 : 172 - 標的パスウェイ数 : 225
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03293069
(ClinicalTrials.gov)
January 30, 201921/9/2017Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral SclerosisConservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis: Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of DeferiproneAmyotrophic Lateral SclerosisDrug: Deferiprone;Drug: Placebo Oral TabletUniversity Hospital, LilleMinistry of Health, FranceRecruiting18 Years75 YearsAll240Phase 2/Phase 3France
2EUCTR2017-003763-35-FR
(EUCTR)
17/05/201805/03/2018conservative iron chelation by deferiprone for amyotrophic lateral sclerosisConservative Iron Chelation by Deferiprone as a disease-modifying Strategy for Amyotrophic Lateral Sclerosis using a Multicentre Parallel group, placebo controlled, Randomized clinical trial - FAIR ALS II De novo Amyotrophic Lateral Sclerosis patients;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: Deferiprone DR
INN or Proposed INN: DEFERIPRONE
centre hospitalier universitaire de LilleNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
240Phase 3France
3NCT02164253
(ClinicalTrials.gov)
September 201320/5/2014Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) PatientsFeasibility and Safety Pilot Therapeutic Study of the Iron Chelator Deferiprone in Amyotrophic Lateral SclerosisALS (Amyotrophic Lateral Sclerosis);Iron OverloadDrug: DeferiproneUniversity Hospital, LilleApoPharmaCompleted18 Years85 YearsAll23Phase 2France
4NCT02880033
(ClinicalTrials.gov)
February 20113/8/2016Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating LymphocytesModulation of Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes of Patients With Parkinson's Disease or Amyotrophic Lateral SclerosisParkinson's Disease;Amyotrophic Lateral Sclerosis;Oxidative Stress;Iron OverloadDrug: deferiprone;Drug: placeboUniversity Hospital, LilleNULLCompleted18 Years80 YearsAll90N/AFrance

6. パーキンソン病


臨床試験数 : 2,298 薬物数 : 2,218 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2015-004344-19-DE
(EUCTR)
07/02/201727/09/2016An international trial of deferiprone in patients with Parkinson’s diseaseA Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients with Parkinson’s Disease - LA48-0215 Parkinson’s disease
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Deferiprone 600 mg delayed release tablet
INN or Proposed INN: DEFERIPRONE
ApoPharmaNULLNot Recruiting Female: yes
Male: yes
140 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noFrance;Canada;Germany;United Kingdom
2NCT02728843
(ClinicalTrials.gov)
October 12, 201631/3/2016Study of Parkinson's Early Stage With DeferiproneA Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients With Parkinson's DiseaseParkinson's DiseaseDrug: Deferiprone;Drug: PlaceboApoPharmaNULLCompleted18 Years80 YearsAll140Phase 2Canada;France;Germany;United Kingdom
3EUCTR2015-003679-31-NL
(EUCTR)
09/08/201624/05/2016New therapeutic strategy in Parkinson’s diseaseConservative iron chelation as a disease-modifying strategy in Parkinson’s disease - FAIRPARK II De Novo Parkinson’s disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: Deferiprone DR
INN or Proposed INN: DEFERIPRONE
Centre Hospitalier Régional et Universitaire de LilleNULLNot RecruitingFemale: yes
Male: yes
338Phase 2Portugal;Czech Republic;Spain;Austria;Netherlands
4EUCTR2015-004344-19-FR
(EUCTR)
29/06/201620/04/2016An international trial of deferiprone in patients with parkinson’s diseaseA Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients with Parkinson’s Disease - LA48-0215 Parkinson’s disease
MedDRA version: 19.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Deferiprone 600 mg delayed release tablet
INN or Proposed INN: DEFERIPRONE
ApoPharma Inc.NULLNot Recruiting Female: yes
Male: yes
140 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited States;France;Canada;Germany;Italy;United Kingdom
5EUCTR2015-003679-31-CZ
(EUCTR)
23/06/201628/01/2016New therapeutic strategy in Parkinson’s diseaseConservative iron chelation as a disease-modifying strategy in Parkinson’s disease - FAIRPARK II De Novo Parkinson’s disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: Deferiprone DR
INN or Proposed INN: DEFERIPRONE
Centre Hospitalier Régional et Universitaire de LilleNULLNot RecruitingFemale: yes
Male: yes
338Phase 2Portugal;Czech Republic;Spain;Austria;Netherlands
6EUCTR2015-003679-31-PT
(EUCTR)
18/04/201628/01/2016New therapeutic strategy in Parkinson’s diseaseConservative iron chelation as a disease-modifying strategy in Parkinson’s disease - FAIRPARK II De Novo Parkinson’s disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: Deferiprone DR
INN or Proposed INN: DEFERIPRONE
Centre Hospitalier Régional et Universitaire de LilleNULLNot RecruitingFemale: yes
Male: yes
338Phase 2Portugal;Czech Republic;Spain;Austria;Netherlands
7EUCTR2015-003679-31-AT
(EUCTR)
06/04/201611/01/2016New therapeutic strategy in Parkinson’s diseaseConservative iron chelation as a disease-modifying strategy in Parkinson’s disease - FAIRPARK II De Novo Parkinson’s disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: Deferiprone DR
INN or Proposed INN: DEFERIPRONE
Centre Hospitalier Régional et Universitaire de LilleNULLNot RecruitingFemale: yes
Male: yes
372Phase 2Portugal;France;Czech Republic;Spain;Austria;Netherlands;Germany;United Kingdom
8EUCTR2015-004344-19-GB
(EUCTR)
31/03/201616/02/2016An international trial of deferiprone in patients with Parkinson’s diseaseA Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients with Parkinson’s Disease - LA48-0215 Parkinson’s disease
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Deferiprone 600 mg delayed release tablet
INN or Proposed INN: DEFERIPRONE
ApoPharmaNULLNot RecruitingFemale: yes
Male: yes
140Phase 2France;Canada;Germany;United Kingdom
9EUCTR2015-003679-31-ES
(EUCTR)
21/03/201613/01/2016New therapeutic strategy in Parkinson?s diseaseConservative iron chelation as a disease-modifying strategy in Parkinson?s disease: a multicentre, parallel-group, placebo-controlled, randomized clinical trial of deferiprone - FAIRPARK II De Novo Parkinson?s disease
MedDRA version: 18.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Ferriprox 500 mg
Product Name: Deferiprone DR
INN or Proposed INN: DEFERIPRONE
Centre Hospitalier Régional et Universitaire de LilleNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
338Phase 3Spain
10NCT02655315
(ClinicalTrials.gov)
February 9, 20167/1/2016Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's DiseaseConservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease. European Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of DeferiproneParkinson DiseaseDrug: Deferiprone;Drug: PlaceboUniversity Hospital, LilleEuropean Commission;ApoPharmaActive, not recruitingN/A80 YearsAll372Phase 2Austria;Czechia;France;Germany;Netherlands;Portugal;Spain;United Kingdom;Czech Republic
11EUCTR2015-003679-31-FR
(EUCTR)
25/01/201625/02/2016New therapeutic strategy in Parkinson’s diseaseConservative iron chelation as a disease-modifying strategy in Parkinson’s disease - FAIRPARK II De Novo Parkinson’s disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: Deferiprone DR
INN or Proposed INN: DEFERIPRONE
Centre Hospitalier Régional et Universitaire de LilleNULLNot RecruitingFemale: yes
Male: yes
338Phase 2Portugal;France;Czech Republic;Spain;Austria;Netherlands
12NCT01539837
(ClinicalTrials.gov)
February 201222/2/2012A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's DiseaseA Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's DiseaseParkinson's DiseaseDrug: Deferiprone 20mg;Drug: Placebo;Drug: Deferiprone 30mgImperial College LondonNULLCompleted50 Years75 YearsAll22Phase 2United Kingdom
13EUCTR2011-001148-31-GB
(EUCTR)
13/09/201117/08/2011A pilot clinical trial with the iron chelator Deferiprone in Parkinson's disease - Pilot clinical trial iron chelator Deferiprone in Parkinson's Vs1A pilot clinical trial with the iron chelator Deferiprone in Parkinson's disease - Pilot clinical trial iron chelator Deferiprone in Parkinson's Vs1 Parkinson's diseaseTrade Name: Ferrprox (Deferiprone)
Product Name: Deferiprone (Ferriprox)
INN or Proposed INN: Deferiprone
Imperial College LondonNULLNot Recruiting Female: yes
Male: yes
48 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited Kingdom
14NCT02880033
(ClinicalTrials.gov)
February 20113/8/2016Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating LymphocytesModulation of Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes of Patients With Parkinson's Disease or Amyotrophic Lateral SclerosisParkinson's Disease;Amyotrophic Lateral Sclerosis;Oxidative Stress;Iron OverloadDrug: deferiprone;Drug: placeboUniversity Hospital, LilleNULLCompleted18 Years80 YearsAll90N/AFrance
15NCT00943748
(ClinicalTrials.gov)
October 200920/7/2009Efficacy and Safety of the Iron Chelator Deferiprone in Parkinson's DiseaseEfficacy and Safety of the Iron Chelator Deferiprone on Iron Overload in the Brain in Parkinson's DiseaseParkinson's DiseaseDrug: deferiprone;Drug: placeboUniversity Hospital, LilleNULLCompleted30 Years80 YearsBoth40Phase 2/Phase 3France

18. 脊髄小脳変性症(多系統萎縮症を除く。)


臨床試験数 : 71 薬物数 : 101 - (DrugBank : 30) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 65
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2009-010865-22-IT
(EUCTR)
06/05/200916/04/2009An open-label, single treatment, safety and efficacy, long-term study of deferiprone in subjects with Friedreich?s ataxia - NDAn open-label, single treatment, safety and efficacy, long-term study of deferiprone in subjects with Friedreich?s ataxia - ND patients affected by Friedreich AtaxiaINN or Proposed INN: DeferiproneAPOPHARMA INC., TORONTO, ONTARIONULLNot RecruitingFemale: yes
Male: yes
74Belgium;France;Spain;Italy
2EUCTR2007-003331-23-IT
(EUCTR)
16/07/200810/07/2008A study investigating the safety and tolerability of deferiprone in patients with Friedreich's Ataxia - NDA study investigating the safety and tolerability of deferiprone in patients with Friedreich's Ataxia - ND patients affected by Friedreich Ataxia
MedDRA version: 9.1;Level: LLT;Classification code 10017374;Term: Friedreich's ataxia
Product Name: Deferiprone
INN or Proposed INN: Deferiprone
APOPHARMA INC., TORONTO, ONTARIONULLNot RecruitingFemale: yes
Male: yes
80United Kingdom;Belgium;France;Spain;Italy

120. 遺伝性ジストニア


臨床試験数 : 25 薬物数 : 22 - (DrugBank : 4) / 標的遺伝子数 : 2 - 標的パスウェイ数 : 2
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04184453
(ClinicalTrials.gov)
December 23, 201929/11/2019Clinical Curative Effect Evaluation Study of Treatment of Oral Deferiprone Tablets in Aceruloplasminaemia PatientsClinical Curative Effect Evaluation Study of Treatment of Oral Deferiprone Tablets in Aceruloplasminaemia PatientsAceruloplasminemiaDrug: Deferiprone treatedFirst Affiliated Hospital of Fujian Medical UniversityNULLRecruiting18 Years80 YearsAll5Early Phase 1China
2NCT02635841
(ClinicalTrials.gov)
February 10, 201617/12/2015Compassionate Use of Deferiprone in Patients With PKANThe Compassionate Use of Deferiprone in Patients With Pantothenate Kinase-Associated NeurodegenerationPantothenate Kinase-Associated NeurodegenerationDrug: DeferiproneChiesi Canada CorpNULLAvailable7 YearsN/AAllNULL
3EUCTR2014-001427-79-GB
(EUCTR)
30/12/201505/11/2015An international open label trial of deferiprone in patients with iron storage brain disorders - an extension to TIRCON2012V1 (a randomised controlled trial of deferiprone in patients with iron storage brain disorders).Long-term Safety and Efficacy Study of Deferiprone in Patients with Pantothenate Kinase-Associated Neurodegeneration (PKAN) - TIRCON2012V1-EXT Pantothenate Kinase-Associated Neurodegeneration (PKAN)
MedDRA version: 18.1;Level: PT;Classification code 10053643;Term: Neurodegenerative disorder;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Ferriprox
Product Name: Deferiprone 80 mg/mL oral solution
INN or Proposed INN: Deferiprone
Other descriptive name: Deferiprone
ApoPharma IncNULLNot RecruitingFemale: yes
Male: yes
89Phase 3United States;Germany;Italy;United Kingdom
4EUCTR2014-001427-79-DE
(EUCTR)
27/03/201527/03/2015An 18-month extension of an international trial of deferiprone in patients with iron storage brain disordersLong-term Safety and Efficacy Study of Deferiprone in Patients with Pantothenate Kinase-Associated Neurodegeneration (PKAN) - TIRCON Pantothenate kinase-associated neurodegeneration (PKAN);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: deferiprone 80 mg/mL oral solution
INN or Proposed INN: DEFERIPRONE
ApoPharma Inc.NULLNot RecruitingFemale: yes
Male: yes
90Phase 3United States;Germany;Italy;United Kingdom
5NCT02174848
(ClinicalTrials.gov)
June 20145/6/2014Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated NeurodegenerationLong-term Safety and Efficacy Study of Deferiprone in Patients With Pantothenate Kinase-Associated Neurodegeneration (PKAN)Pantothenate Kinase-Associated NeurodegenerationDrug: Deferiprone oral solutionApoPharmaNULLCompleted5 YearsN/AAll68Phase 3United States;Germany;Italy;United Kingdom
6EUCTR2012-000845-11-GB
(EUCTR)
24/10/201319/09/2013An international trial of deferiprone in patients with iron storage brain disordersA randomized, double-blind, placebo-controlled trial of deferiprone in patients with pantothenate kinase-associated neurodegeneration (PKAN) - TIRCON Pantothenate Kinase-Associated Neurodegeneration (PKAN)
MedDRA version: 16.0;Level: PT;Classification code 10053643;Term: Neurodegenerative disorder;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Ferriprox
Product Name: Deferiprone 80 mg/mL oral solution (Ferriprox)
INN or Proposed INN: Deferiprone
Other descriptive name: Deferiprone
ApoPharma IncNULLNot Recruiting Female: yes
Male: yes
90 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): noUnited States;Poland;Germany;Italy;United Kingdom
7EUCTR2012-000845-11-IT
(EUCTR)
24/10/201331/07/2013An international trial of deferiprone in patients with iron storage brain disordersA randomized, double-blind, placebo-controlled trial of deferiprone in patients with pantothenate kinase-associated neurodegeneration (PKAN) - TIRCON Pantothenate kinase-associated neurodegeneration (PKAN);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: Deferiprone 80 mg/mL oral solution
INN or Proposed INN: Deferiprone
Other descriptive name: Deferiprone
ApoPharma Inc.NULLNot RecruitingFemale: yes
Male: yes
90Phase 3United States;Poland;Germany;United Kingdom;Italy
8NCT01741532
(ClinicalTrials.gov)
December 13, 20123/12/2012Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN)A Randomized, Double-blind, Placebo-controlled Trial of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN)Pantothenate Kinase-Associated NeurodegenerationDrug: Deferiprone oral solution;Drug: PlaceboApoPharmaFood and Drug Administration (FDA)Completed4 YearsN/AAll89Phase 3United States;Germany;Italy;United Kingdom;Poland
9EUCTR2012-000845-11-DE
(EUCTR)
16/07/201230/03/2012An international trial of deferiprone in patients with iron storage brain disordersA randomized, double-blind, placebo-controlled trial of deferiprone in patients with pantothenate kinase-associated neurodegeneration (PKAN) - TIRCON Pantothenate kinase-associated neurodegeneration (PKAN);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: Deferiprone 80 mg/mL oral solution
INN or Proposed INN: Deferiprone
Other descriptive name: Deferiprone
ApoPharma Inc.NULLNot RecruitingFemale: yes
Male: yes
90Phase 3United States;Poland;Germany;United Kingdom;Italy
10EUCTR2008-003059-56-IT
(EUCTR)
29/07/200818/07/2008Phase II trial to assess safety and efficacy of Iron chelating agent Deferiprone in patients with Pantothenate Kinase-Associated Neurodegeneration ? ICAND ? Trial - NDPhase II trial to assess safety and efficacy of Iron chelating agent Deferiprone in patients with Pantothenate Kinase-Associated Neurodegeneration ? ICAND ? Trial - ND PKAN
MedDRA version: 9.1;Level: HLT;Classification code 10042259;Term: Structural brain disorders NEC
Trade Name: FERRIPROX*100CPR RIV 500MG
INN or Proposed INN: Deferiprone
ISTITUTO NEUROLOGICO CARLO BESTANULLNot RecruitingFemale: yes
Male: yes
Phase 2Italy

122. 脳表ヘモジデリン沈着症


臨床試験数 : 4 薬物数 : 9 - (DrugBank : 3) / 標的遺伝子数 : 0 - 標的パスウェイ数 : 0
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-UMIN000021218
2024/09/3026/02/2016An efficacy of iron chelator to superficial siderosisAn efficacy of iron chelator to superficial siderosis - EICHSS superficial siderosis of CNSdeferiproneDepartment of Neurology, Tokyo Medical and Dental UniversityNULLRecruiting20years-oldNot applicableMale and Female5Not applicableJapan
2JPRN-jRCTs031180438
01/04/201927/03/2019Evaluation of iron chelator administration, and cochlear implantation for superficial siderosisEvaluation of iron chelator administration, and cochlear implantation for superficial siderosis - ECHACISS Superficial siderosis
siderosis, cerebellar ataxia, hearing loss, superficial siderosis
1. Administration of Deferiprone orally 30mg/kg after every meal for 36 months.
2. Artificial cochlear implantation for severe hearing disturbance
Sanjo NobuoNULLRecruiting>= 20age oldNot applicableBoth50N/AJapan

233. ウォルフラム症候群


臨床試験数 : 9 薬物数 : 15 - (DrugBank : 7) / 標的遺伝子数 : 11 - 標的パスウェイ数 : 41
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02882477
(ClinicalTrials.gov)
December 201617/7/2016Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based TherapyTreatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone, and Incretin Based TherapyDiabetes Mellitus;Iron Metabolism Disorders;Gastroduodenal Ulcer;Optic Atrophy;Sensorineural Hearing Loss;Platelet DysfunctionDrug: Deferiprone;Drug: Acetylcysteine;Drug: Sitagliptin and MetforminHadassah Medical OrganizationNULLNot yet recruiting3 YearsN/ABoth20Phase 2/Phase 3Israel